LFBC(SZ:002513) Zheng Quan Zhi Xing·2025-09-02 16:14Core Viewpoint - The article discusses the lifting of restrictions on the shares of Jiangsu Lanfeng Bio-chemical Co., Ltd. following a major asset restructuring, detailing the compliance of shareholders with their commitments and the financial implications of this event [1][7]. Summary by Sections 1. Basic Situation of Restricted Shares - Jiangsu Lanfeng Bio-chemical Co., Ltd. completed a major asset restructuring by acquiring 100% equity of Shaanxi Ark Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments, with the new shares being registered as restricted shares [1]. 2. Shareholders' Commitments and Compliance - The shareholders applying for the lifting of restrictions, Ren Wenbin and Chen Jing, made commitments regarding the transfer of shares based on the duration of their asset ownership, with specific percentages of shares allowed for transfer at different time intervals [2][3]. - Both shareholders adhered to their commitments during the lock-up period and have not transferred their restricted shares [3]. 3. Performance Compensation Agreement - The performance compensation agreement stipulated that if Ark Pharmaceutical's net profit fell below certain thresholds for the years 2015, 2016, and 2017, the shareholders would compensate Jiangsu Lanfeng Bio-chemical in cash or shares [3]. - The shareholders fulfilled their compensation obligations for the years 2015 and 2016, but not for 2017, leading to a total compensation amount of 60.53 million yuan [3]. 4. Legal Proceedings and Compensation Payment - Jiangsu Lanfeng Bio-chemical filed a lawsuit against the shareholders for overdue performance compensation, resulting in a court ruling that required Ren Wenbin to pay 2.9561 million yuan and Chen Jing to pay 1.0749 million yuan, both with penalties [4]. - The company has received all compensation payments from the shareholders, fulfilling their obligations [4]. 5. Details of Restricted Shares Lifting - The lifting of restrictions on the shares will allow 1,339,746 shares to be listed for trading, which represents 0.357% of the company's total shares [4][6]. - The shares will become tradable on September 5, 2025 [4]. 6. Financial Advisor's Opinion - The independent financial advisor confirmed that the shareholders complied with their commitments and that the lifting of restrictions aligns with relevant laws and regulations, ensuring accurate and complete disclosure of information by Jiangsu Lanfeng Bio-chemical [7].